- Conditions
- Macular Degeneration
- Interventions
- Epi-Rad90™ Ophthalmic System, ranibizumab
- Device · Drug
- Lead sponsor
- NeoVista
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 130
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Age-Related Maculopathy, Choroidal Neovascularization
- Interventions
- Ranibizumab, Verteporfin
- Drug
- Lead sponsor
- Oklahoma State University Center for Health Sciences
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Tulsa, Oklahoma
- Conditions
- Age Related Macular Degeneration
- Interventions
- Intravitreal Aflibercept injection
- Drug
- Lead sponsor
- Retina Research Institute, LLC
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • McAllen, Texas
- Conditions
- Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,775 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Choroidal Neovascularization, Age-Related Maculopathy
- Interventions
- dexamethasone, ranibizumab
- Drug · Biological
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- episcleral brachytherapy
- Radiation
- Lead sponsor
- Salutaris Medical Devices, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 2
- States / cities
- ‘Aiea, Hawaii • Oak Forest, Illinois
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)
- Drug
- Lead sponsor
- Light Sciences LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Retinal Artery Occlusions, Polypoidal Choroidal Vasculopathy, Retinal Arterial Macroaneurysm, Juxtafoveal Telangiecasia, Central Serous Chorioretinopathy
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 7 Years to 100 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Choroidal Neovascularization, Macular Degeneration
- Interventions
- verteporfin, ranibizumab, dexamethasone
- Drug
- Lead sponsor
- QLT Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
- Conditions
- Presumed Ocular Histoplasmosis
- Interventions
- Faricimab Injection [Vabysmo]
- Drug
- Lead sponsor
- Cincinnati Eye Institute, Southwest Ohio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Dayton, Ohio
- Conditions
- Ocular Histoplasmosis Syndrome
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Retina Associates of Kentucky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Age-related Macular Degeneration
- Interventions
- Fovista® (anti-PDGF BB) plus anti-VEGF
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascularization, Central Serous Chorioretinopathy
- Interventions
- Not listed
- Lead sponsor
- Sequenom, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Macular Degeneration
- Interventions
- pegaptanib sodium
- Drug
- Lead sponsor
- Eyetech Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Bridgeport, Connecticut • Hamden, Connecticut + 16 more
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- iSONEP
- Biological
- Lead sponsor
- Lpath, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 2 more
- Conditions
- Polypoidal Choroidal Vasculopathy
- Interventions
- fosbretabulin, Saline
- Drug
- Lead sponsor
- Mateon Therapeutics
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Age-related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Macular Degeneration
- Interventions
- TAC-PF, Triamcinolone Acetonide
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Los Angeles, California • Miami, Florida + 19 more
- Conditions
- Macular Degeneration
- Interventions
- NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks
- Drug
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Irvine, California + 28 more
- Conditions
- Macular Degeneration
- Interventions
- Celecoxib
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- IBI-20089/Lucentis
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age Related Macular Degeneration
- Interventions
- ForeseeHome
- Device
- Lead sponsor
- Notal Vision Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- ADVM-022
- Genetic
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more